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AbstrAct
Introduction Chronic kidney disease (CKD) is associated 
with an increased risk of cardiovascular disease and 
mortality, which is thought to be caused by increased 
propensity towards vascular calcification (VC). Magnesium 
(Mg) inhibits phosphate-induced VC in vitro and in 
animal models and serum Mg is inversely associated 
with cardiovascular mortality in predialysis CKD and in 
end-stage renal disease. This paper will describe the 
design and rationale of a randomised double-blinded 
placebo-controlled multicentre clinical trial, which will 
investigate whether oral Mg supplementation can prevent 
the progression of coronary artery calcification (CAC) in 
subjects with predialysis CKD.
Methods and analysis We will randomise 250 subjects 
with estimated glomerular filtration rate of 15 to 45 mL/
min/1.73 m2 to 12 months treatment with either slow-
release Mg hydroxide 30 mmol/day or matching placebo 
in a 1:1 ratio. The primary end point is change in CAC 
score as measured by CT at baseline and after 12 months 
treatment. Secondary end points include change in 
pulse wave velocity, bone mineral density, measures of 
mineral metabolism and clinical end points related to 
cardiovascular and renal events.
Ethics and dissemination This trial has been approved 
by the local biomedical research ethics committees 
and data protection agencies and will be performed 
in accordance with the latest revision of the Helsinki 
Declaration. The trial will examine for the first time the 
effect of increasing the uptake of a putative VC inhibitor 
(ie, Mg) on progression of CAC in subjects with predialysis 
CKD.
Trial registration number NCT02542319, pre-results.
IntroductIon
Chronic kidney disease (CKD) is prevalent 
in approximately 13% of the general popula-
tion1 and is associated with an increased risk 
of developing cardiovascular disease (CVD).2 
This is partly due to an accumulation of 
traditional CVD risk factors (eg, hypertension, 
dyslipidaemia, diabetes mellitus (DM), age), 
but even after adjusting for these risk factors, 
CKD is still associated with an increased risk 
of CVD as compared with the general popula-
tion.2 This implies that other non-traditional 
CVD risk factors associated with CKD are 
causing an increased risk of CVD. Vascular 
calcification (VC) is highly prevalent among 
persons with CKD3 and is thought to be partly 
responsible for this increased risk of CVD. 
Indeed, indirect measurements of VC (eg, 
coronary artery calcifications score (CAC), 
pulse wave velocity (PWV) and pulse pres-
sure) have been associated with increased risk 
of CVD (particularly heart failure) in persons 
with CKD.4–6 Thus, any intervention that 
could prevent the development or progres-
sion of VC is presumed also to reduce the risk 
of CVD and death.
In subjects with CKD, disturbances in the 
mineral and bone metabolism are thought to 
be one of the main causes of VC. As kidney 
function declines, phosphate (PO4) accu-
mulates in serum and binds to calcium (Ca). 
Once the concentration of Ca/PO4 particles 
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Strengths and limitations of this study
 ► Randomised, double-blind, placebo-controlled study 
design.
 ► Multicentre trial.
 ► Sufficient sample size and follow-up.
 ► Novel intervention.
 ► Surrogate end points, no hard clinical endpoints, for 
example, cardiovascular events or mortality.
 ► Unknown whether results can be extrapolated to 
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in serum exceed their saturation point, they precipitate 
and induce the vascular smooth muscle cells (VSMC) of 
the arteries to undergo a dedifferentiation into an osteo-
genic phenotype in which the VSMC calcify and stiffen.7 
So far, efforts to prevent VC in CKD have been focused 
on the concentration of calcification promoters in serum 
(ie, PO4 and Ca), but recently focus has shifted to also 
consider the concentration of calcification inhibitors in 
serum. In vitro studies of PO4-induced VC and animal 
studies of CKD and VC have consistently shown that 
increasing magnesium (Mg) levels prevents or reduces 
the development of VC8–15 by increasing the expression 
of intracellular calcification inhibitors and decreasing 
the expression of calcification promoters and PO4 trans-
porters. Several epidemiological studies have shown that 
higher levels of serum Mg are associated with improved 
survival in patients with CKD16 and end-stage renal disease 
(ESRD).17–24 Also, higher levels of serum Mg are associ-
ated with reduced incidence and progression of CKD25–27 
and with lower prevalence of VC in CKD.28
In this setting, increasing the Mg concentration in 
serum by means of Mg supplementation is an attractive 
prospect. Two small clinical trials of Mg supplementation 
in ESRD have shown that this intervention can reduce 
the progression of carotid intima/media thickness (a 
proxy for VC) with no incidences of toxic hypermagne-
saemia.29 30 So far, no clinical trials have investigated the 
effect of Mg supplementation on VC in predialysis CKD. 
We therefore posed the research question of whether Mg 
supplementation is effective in preventing the progres-
sion of VC in CKD.
In this paper, we will describe the design and rationale 
of our randomised placebo-controlled double-blinded 
multicentre clinical trial designed to investigate whether 
52 weeks of treatment with oral Mg supplementation can 
prevent the progression of CAC in subjects with CKD 
stage 3b-4.
Methods and analysIs
study design and population
This trial is an investigator-initiated double-blind place-
bo-controlled multicentre clinical trial being performed 
at 10 sites in departments of nephrology in Denmark and 
Norway. We will include adult persons with CKD stage 
3b-4 whom we consider to be at increased risk of VC 
based on serum Mg and PO4. The full list of inclusion 
and exclusion criteria is shown in figure 1.
study intervention
The subjects participating in the trial will be randomised 
in a ratio of 1:1 to 52 weeks treatment with either oral 
slow-release Mg hydroxide (Mablet 360 mg, Gunnar 
Kjems, Denmark) twice daily or matching placebo twice 
daily (figure 2). Mablet is used for Mg supplementation 
and one tablet containing 360 mg of Mg hydroxide is 
equivalent to 15 mmol of elemental Mg, and the interven-
tion will therefore consist of a daily dose of 30 mmol of 
elemental Mg. Mg hydroxide and placebo tablets are iden-
tical in appearance, odour, constituents and containers 
and do not contain calcium. The study medication has 
been packed in consecutively numbered containers 
according to a computer-generated randomisation list 
and will be administered to subjects consecutively as they 
enter the trial. The randomisation will be stratified based 
on enrolment site and DM. Both subjects and investiga-
tors will be blinded to the study medication during the 
course of the trial.
study visits
All persons being followed in the outpatient clinics at the 
participating sites will be screened for eligibility prior to 
their planned appointments in the clinics and offered 
participation in the trial.
At week 0, subjects will give written informed consent 
to participate in the trial, and will have their relevant 
medical history recorded along with anthropomorphic 
measurements. After this, they will undergo a multis-
lice ECG gated CT scan of the coronary arteries of their 
heart to calculate the extent of any VC based on CAC by 
the Agatston method.31 In addition, subjects will have 
fasting blood samples drawn for assessment of kidney 
function, electrolytes, mineral metabolism and serum 
calcification propensity (T50).
32 Samples from a 24-hour 
urine collection will be collected to assess urinary excre-
tion of minerals and protein, and a resting ECG will be 
performed to assess length of the PQ interval and the 
corrected QT interval (QTc). At selected sites, subjects 
will also undergo measurement of bone mineral density 
(BMD) of their lumbar vertebrae and hip during their CT 
scan, and arterial tonometry will be performed to assess 
carotid-femoral PWV (CF-PWV) and radial PWA (see 
figure 3 for the full list of assessments at study visits).
Following the baseline visit, each subject will be seen 
for follow-up visits at 13-week intervals (ie, week 13, week 
26 and week 39), at which times subjects will have fasting 
blood samples drawn to assess safety of the intervention 
(see the Safety monitoring section), 24 hours urine collec-
tions will be sampled to assess mineral excretion and study 
medication will be dispensed. Adherence to the interven-
tion will be assessed by pill count of any remaining study 
medication from the previous study visit.
At the final study visit (week 52), subjects will repeat 
baseline measurements, after which they will return to 
their regular outpatient care.
safety monitoring
All subjects will have serum Mg and potassium evalu-
ated at each follow-up visit and will be questioned on 
any potential side effects to the treatment, particularly 
gastrointestinal side effects such as loosening of stool or 
diarrhoea. If at any time serum Mg exceeds 1.80 mmol/L, 
the subject will cease study medication, and a follow-up 
blood sample for serum Mg will be drawn 2 weeks later. 
If at this time serum Mg still exceeds 1.50 mmol/L, the 
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Figure 1 Inclusion and exclusion criteria.
Figure 2 Trial design of effect of oral magnesium on 
vascular calcification in chronic kidney disease. BID, twice 
daily.
otherwise continue in the trial as planned. If serum Mg 
does not exceed 1.50 mmol/L the subject will continue 
study medication at half dose (ie, only take study medica-
tion once daily) and a follow-up blood sample for serum 
Mg will be drawn again 2 weeks later. If at this time serum 
Mg exceeds 1.50 mmol/L, the subject will permanently 
cease study medication, but will otherwise continue in 
the trial as planned. Any incidences of hyperkalaemia will 
be handled at the discretion of the local site investigator.
Adverse events and serious adverse events will be 
recorded and reported to an independent data and safety 
monitoring board.
concomitant medical therapy
Subjects should not initiate treatment with Mg-containing 
medication, laxatives or antacids during the trial. Also, 
investigators should avoid initiating medical therapy that 
might reduce Mg absorption in the gut or Mg loss in the 
kidneys. Therefore, investigators should avoid initiating 
proton pump inhibitors unless necessary for serious 
gastrointestinal conditions (histamine H2-receptor antag-
onist may be considered as an alternative), and if possible 
investigators should not initiate or increase doses of thia-
zide diuretics, thiazide-like diuretics or loop diuretics for 
treatment of hypertension and should instead use other 
antihypertensive agents. All medications and any changes 
to these will be recorded at baseline and at each follow-up 
visit.
study end points
The primary end point of this trial is the difference in 
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Figure 3 Schedule for enrolment, interventions and assessments.
the two groups. CAC scores will be calculated inde-
pendently by two observers trained in CAC scoring. 
In the event of >5% difference in calculated CAC 
score, the score will be recalculated by both observers 
together for a final CAC score. Subgroup analyses will 
be performed to assess the effect of the intervention 
on CAC progression in subjects with and without DM, 
in subjects with CAC >0 and CAC=0 at baseline and in 
subjects divided into tertiles of T50.
Secondary end points include change and CF-PWV 
and PWA, change in BMD, change in markers of 
mineral metabolism, difference in rate of estimated 
glomerular filtration rate (eGFR) decline, as well as 
clinical end points such as incidence of major adverse 
cardiovascular events (myocardial infarction, stroke, 
new-onset heart failure or hospitalisation for heart 
failure and limb amputation or revascularisation due 
to peripheral arterial occlusion), all-cause and cardio-
vascular mortality, adverse and serious adverse events 
and incidence of ESRD (defined as dialysis initiation 
or kidney transplantation). In addition, subjects will 
be contacted 5 years after their participation in the 
study to assess whether Mg supplementation reduces 
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statistical analysis
Data that follow a normal distribution will be described 
as mean±SD and non-normal data will be described 
as median with IQR. The primary end point will be 
compared between the two treatment groups using an 
unpaired Student’s t-test (possibly after logarithmic trans-
formation if the data do not follow a normal distribution) 
and as intention to treat. Changes and between-group 
differences in secondary end points will be analysed 
using paired and unpaired Student’s t-tests or Wilcoxon 
and Mann-Whitney tests for continuous variables and χ2 
or Fisher’s exact test for dichotomous variables. Linear 
mixed models will be used to analyse variables with 
repeated measures. Linear and logistic regression anal-
yses with adjustment for various covariates will be applied 
to baseline data to investigate any associations with the 
change in various parameters as well as any associations 
with clinical events.
The data analysis will be performed blinded to the 
treatment allocation.
sample size calculation
In a prospective observational study of 53 patients with 
CKD stage 3–5, 27 patients (51%) had CAC at baseline.33 
Of these 27 patients, the annual progression of CAC score 
was 275.6±69.2 (mean and SE of the mean). The SD at 
baseline for CAC score in this group of 27 patients was 
360. We consider an annual difference in CAC score of 
200 to be the minimally relevant difference, since a differ-
ence in change of this magnitude has been shown in a 
previous trial of phosphate binder treatment in CKD 
stage 3–5.34 With a power (β) of 20% in a two-sample t-test 
with a significance (α) of 5% the sample size must be 52 
per group, when considering only the data concerning 
the patients who had CAC at baseline. However, since 
we do not know whether subjects will have CAC or not 
at baseline, we must assume that the prevalence (51%) 
and progression of CAC in our population will be similar 
to the reference study. Based on this, we therefore need 
108 subjects per group. We anticipate a dropout rate of 
15%, and the trial will therefore include 250 subjects 
randomised in a ratio of 1:1.
ethics and dissemination
All subjects will give written informed consent prior 
to initiating the trial and the trial will be performed 
according to the lasted revision of the Helsinki Declara-
tion. We applied for and received approval to conduct the 
trial from the Danish and Norwegian National Commit-
tees on Biomedical Research Ethics (H-15009846 and REK 
Sør-Øst D 2015/2428, respectively) as well as the Danish 
and Norwegian Data Protection Agencies (2012-58-0004 
and 16–077, respectively). Since Mablet is registered as 
a supplement and not a drug, the trial does not require 
approval from the Danish or Norwegian medical agen-
cies. We have established an independent data safety 
monitoring board at Nordsjællands Hospital, Hillerød, 
Denmark, which will monitor all serious adverse events 
occurring during the trial. Lastly, we registered the trial at 
www. clinicaltrials. gov (NCT02542319) prior to initiating 
the trial.
We began recruitment in December 2015 and expect 
to have completed recruitment by September 2017 and 
completed data collection by September 2018. The final 
results of the trial will be published in international 
peer-reviewed journals.
dIscussIon
assessing risk of Vc progression
Serum PO4 is the only modifiable risk factor that has 
been associated with progression of CAC in predialysis 
CKD,33 and all published in vitro and animal studies of 
Mg in PO4-induced VC have shown that Mg ameliorates 
the development of VC.8–15 Thus, PO4 likely promotes 
CAC progression in CKD, and increasing levels of Mg 
seem to prevent VC induced by PO4. Therefore, it seems 
reasonable to consider patients with ‘increased’ PO4 and 
‘reduced’ levels of Mg to be at risk of CAC progression.
In a previous randomised clinical trial of CAC progres-
sion in patients with predialysis CKD and no history of 
coronary artery disease, previous stroke, DM or dyslipi-
daemia (ie, free of important conventional risk factors 
associated with VC and thus reflecting ‘uremic’ causes 
of VC), the placebo group had a mean serum PO4 of 
1.26 mmol/L at baseline and experienced an annual 
progression of CAC by approximately 200.34 Unfortu-
nately, no trials in predialysis CKD have examined the 
quantitative role of Mg in CAC progression. However, one 
cross-sectional study found that for PO4 <1.10 mmol/L 
there was no relationship between serum Mg and CAC 
density, while for PO4 >1.10 mmol/L there was an almost 
linear inverse relationship between serum Mg and CAC 
density.28 Based on this, we have made the assumptions 
that serum PO4 >1.10 mmol/L is necessary for serum 
Mg to exert its calcification inhibitory effects, and serum 
PO4 >1.26 mmol/L is predictive of CAC progression when 
serum Mg is unknown. We have therefore semiarbitrarily 
set our threshold for risk of CAC progression at serum 
Mg <0.82 (ie, below the mean laboratory value of Mg) 
when serum PO4 >1.15 mmol/L, or serum Mg <0.92 (ie, 
below the upper laboratory limit of Mg) when serum 
PO4 >1.30 mmol/L.
We acknowledge that several other factors involved 
in mineralisation are likely involved in the propensity 
towards CAC, and that our assumption does not account 
for these. However, there is no available evidence linking 
these other factors with risk of CAC progression and most 
are not implemented in clinical practice. Therefore, we 
have chosen a pragmatic approach to assessment of VC 
risk based only on serum PO4 and Mg.
safety and efficacy of Mg supplementation
Prior to the design of this trial, we conducted a 
randomised double-blind placebo-controlled clinical 
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slow-release Mg hydroxide supplementation in subjects 
with eGFR <60 mL/min/1.73 m2 and low or low-normal 
serum Mg, and found that a dose of 30 mmol/day was 
necessary to achieve statistically significant increases in 
serum Mg.35 This intervention was found to be safe (ie, 
no incidences of serum Mg>2.0 mmol/L) and the inci-
dences of gastrointestinal side effects were similar to 
placebo treatment. Also, this intervention increased T50, 
which is believed to reflect the propensity towards ectopic 
calcification and which has been shown to be inversely 
associated with all-cause mortality in a predialysis CKD.36 
The pilot trial was small and of only 8 weeks duration, so 
it is possible that there are side effects or toxicities related 
to the chosen dose of Mg supplementation, which will 
only become manifest after longer treatment periods.
We chose the slow-release Mg hydroxide formulation 
used in this trial because it is cheap and widely available in 
Denmark. Due to its slow-release formulation, it does not 
have the laxative effect usually associated with inorganic 
Mg compounds, although long-term use or high doses are 
known to cause loosening of stool and/or frequent bowel 
movements. It is possible that other organic Mg formula-
tions (eg, Mg citrate) might have greater bioavailability of 
Mg37 38 and fewer gastrointestinal side effects, but to our 
knowledge no clinical trials have examined their safety 
and efficacy in subjects with CKD.
Mg supplementation as a Po4 binder
Given the known PO4-lowering effects of Mg-containing 
PO4 binders,
39 it is possible that the Mg supplementa-
tion used in this trial might also reduce serum PO4. We 
found no effect of Mg supplementation on serum PO4, 
24 hours urine PO4 or intact fibroblast growth factor 23 in 
our previously mentioned trial of Mg supplementation, 
suggesting that the Mg formulation used in this trial does 
not act as a PO4 binder.
35 The size and duration of this 
trial will make it possible to better assess any effects of 
Mg supplementation on PO4 homeostasis, although any 
results must be interpreted with caution, since this trial is 
not designed to address this research question.
limitations of this trial
The main limitation of this trial is that CAC is only a 
surrogate measure for CVD. Even if Mg supplementation 
is effective in reducing the progression of CAC, this trial 
is not powered to assess whether reduced progression of 
CAC reduces the incidence of cardiovascular events or 
mortality.
Although intimal and medial calcification often 
occur simultaneously, calcification due to disturbances 
in mineral and bone metabolism is believed mainly to 
cause medial calcification. CAC by the Agatston method 
measures the product of volume and density of calcium 
in the coronary arteries but cannot differentiate between 
intimal and medial calcification, and thus it is not 
possible to assess whether any changes to CAC are due 
to intimal calcification, medial calcification or both. Mg 
supplementation might also reduce progression of aortic 
calcification and thereby progression of aortic stiffness, 
in which case CF-PWV might be affected by the interven-
tion. CF-PWV will be measured in a subset of the subjects 
participating in the trial.
A further limitation of this trial is that the trial will only 
include subjects with CKD stage 3b-4. Patients with stage 
5 CKD will likely have greater risk of VC progression and 
would therefore potentially have greater benefit of any 
treatment effect. However, since there are no clinical 
trials assessing the safety of Mg supplementation in stage 
5 CKD, we have excluded patients with eGFR <15 mL/
min/1.73 m2 from this trial. It is likely that some subjects 
will progress to stage 5 CKD during the course of the 
trial, and if any of these subjects are randomised to Mg 
supplementation, we will learn more about the safety of 
Mg supplementation in subjects with very low eGFR.
Potential impact of the trial
Previous trials have examined the effect of PO4 binders 
on progression of VC in predialysis CKD with varying 
results.34 40 41 This trial tests a new approach to the preven-
tion of VC, by attempting to increase the uptake of a 
calcification inhibitor instead of limiting the uptake of a 
calcification promoter. If successful, this trial might pave 
the way for larger randomised clinical trials investigating 
the effects of Mg supplementation on cardiovascular 
events and all-cause mortality. Mg supplementation is 
cheap and widely available, which would make this inter-
vention accessible and affordable to all patients with CKD.
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